Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07202884 · ClinicalTrials.gov registry record · Phase 3
A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight
A Phase 3 study of Urinary Incontinence,Stress, sponsored by Eli Lilly and Company.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 1,000
- Enrollment target
- 20
- Study locations
NCT07202884: Recruiting Phase 3 study of Urinary Incontinence,Stress, sponsored by Eli Lilly and Company.
NCT07202884 is a Phase 3 study of Urinary Incontinence,Stress that is actively recruiting participants, run by Eli Lilly and Company. The registered enrollment target is 1,000 participants, above the 153-participant average among 5 other Urinary Incontinence,Stress trials with a reported enrollment target (554% higher). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07202884, a Phase 3 study of Urinary Incontinence,Stress, is actively recruiting participants, sponsored by Eli Lilly and Company.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,000 participants
- Enrollment target
- 20
- Study locations
Study Summary
The GZPS master protocol will support two independent studies, J2A-MC-GZS1 and J2A-MC-GZS2. Each study will see how well and safely orforglipron works in adult female participants with stress urinary incontinence (SUI) who have obesity or overweight. SUI is leaking urine during movement or activity such as coughing or exercising. Participation in the study will last about 58 weeks from screening to safety follow-up.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Orforglipron
Study Locations (20)
Florida
- AMR Clinical - Fort Myers
- Altus Research - Lake Worth
- New Age Medical Research Corporation - Miami
- Emerald Coast OBGYN Clinical Research - Panama City
California
- Matrix Clinical Research - Los Angeles
- Alarcon Urology Center - Montebello
- Prestige Medical Group - Tustin
Alabama
- University of Alabama -The Kirklin Clinic - Birmingham
- AMR Clinical - Mobile
Pennsylvania
- OB/GYN Associates of Erie - Erie
- Clinical Research of Philadelphia - Philadelphia
Texas
- Next Level Urgent Care - Houston
- Innovative Medical Research of Texas - Houston
Virginia
- Health Research of Hampton Roads, Inc. - Newport News
- Urology of Virginia - Virginia Beach
Arizona
- Urologic Surgeons of Arizona - Mesa
Colorado
- Colorado Clinical Research - Lakewood
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2025-09-30 |
| Est. Completion | 2028-03 |
| Phase | Phase 3 |
What NCT07202884 shows while recruiting
NCT07202884 is an interventional study that assigns participants to a tested intervention. Its 1,000 participants enrollment target places it among the larger protocols in the corpus, above the 153-participant average among 5 other Urinary Incontinence,Stress trials with a reported enrollment target (554% higher).
The record links to 1 condition, with Urinary Incontinence,Stress appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07202884 names 20 study sites across 11 states, led by Florida, California, Alabama.
Frequently Asked Questions
What is clinical trial NCT07202884 about?
NCT07202884 is a clinical study titled "A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight". The GZPS master protocol will support two independent studies, J2A-MC-GZS1 and J2A-MC-GZS2. Each study will see how well and safely orforglipron works in adult female participants with stress urinary incontinence (SUI) who have obesity or overweight. SUI is leaking urine during movement or activity ...
What is the current status of trial NCT07202884?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 1,000 participants. The study started on 2025-09-30. Estimated completion is 2028-03.
What conditions does trial NCT07202884 study?
This clinical trial studies the following conditions: Urinary Incontinence,Stress.
What interventions are being tested in trial NCT07202884?
The interventions under investigation include: Placebo (DRUG), Orforglipron (DRUG).
Who is sponsoring clinical trial NCT07202884?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07202884 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Urinary Incontinence,Stress
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Colpopexy and Urinary Reduction Efforts (CARE) Protocol
COMPLETED · Phase 3
-
TENS Analgesia During Outpatient Urethral Bulking for Stress Urinary Incontinence.
RECRUITING · NA
-
Adjustable Continence Therapy (ACT) for the Treatment of Female SUI
RECRUITING · NA
-
Timing of Repeat Voiding Trials After Outpatient Pelvic Floor Surgery
COMPLETED · NA
-
Trial Liposomal Bupivacaine Following Retropubic Suburethral Sling for Stress Urinary Incontinence
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00018044 · 1,000 participants
Study of Mycobacterial Infections
- NCT01036581 · 1,000 participants · NA
Advanced Functional and Structural MRI Techniques for Neuropharmacological Imaging
- NCT01192048 · 1,000 participants
Genetics of Congenital Heart Disease
- NCT01553214 · 1,000 participants · Phase 4
Improving White Blood Cell Collection From Healthy Donors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI